-
Mashup Score: 0
During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation - 1 year(s) ago
Data on efficacy and safety of sorafenib in a neoadjuvant setting for HCC awaiting liver transplantation (LT) are heterogeneous and scarce. We aimed to investigate the trajectory of patients treated with sorafenib while awaiting LT. All patients listed for HCC and treated with sorafenib were included in a monocentric observational study. A clinical and biological evaluation was performed every…
Source: FrontiersCategories: Latest Headlines, TransplantationTweet-
#HCC progression and #sorafenib treatment while awaiting for #Liver #transplantation: results from an observational prospective study https://t.co/WPYcUbzyuL https://t.co/1ZCfQ1PooZ
-
-
Mashup Score: 0
At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results from the final analysis of the RATIONALE-301 study showed that #tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs #sorafenib in patients with unresectable hepatocellular carcinoma. #HCC #lcsm https://t.co/H1HAxHUBOi https://t.co/KmKJulj2Qc
-
-
Mashup Score: 1New Standard-of-Care Therapy for Advanced Liver Cancer - 2 year(s) ago
Stereotactic body radiotherapy plus sorafenib improves survival versus targeted drug alone
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
"In patients w/ advanced #hepatocellularcarcinoma, compared to #sorafenib alone, SBRT prior to sorafenib improved overall survival, PFS, & TTP, w/o a concerning increase in adverse events," reported @ASTRO_Chair, of @pmcancercentre, at #ASTRO22 @ASTRO_org. https://t.co/hRJYhLFzl2
-
-
Mashup Score: 1
The addition of stereotactic body radiation therapy to sorafenib extended OS among patients with advanced hepatocellular carcinoma, results of the randomized phase 3 NRG Oncology/RTOG 1112 trial showed. Data from the study — presented at American Society for Radiation Oncology Annual Meeting — revealed that radiation before sorafenib also delayed tumor progression without compromising
Source: www.healio.comCategories: Latest Headlines, Oncologists2Tweet-
RT @HemOncToday: Adding radiation therapy to #sorafenib extends survival in advanced liver cancer. https://t.co/pu5uhCTsIT #ASTRO22 @ASTRO…
-
-
Mashup Score: 2
The addition of stereotactic body radiation therapy to sorafenib extended OS among patients with advanced hepatocellular carcinoma, results of the randomized phase 3 NRG Oncology/RTOG 1112 trial showed. Data from the study — presented at American Society for Radiation Oncology Annual Meeting — revealed that radiation before sorafenib also delayed tumor progression without compromising
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding radiation therapy to #sorafenib extends survival in advanced liver cancer. https://t.co/pu5uhCTsIT #ASTRO22 @ASTRO_org #radonc #medphys #HemOnc #OncAlert #MedEd #livercancer #radiation #Nexavar @BayerUS
-
-
Mashup Score: 1
Background Use of kinase inhibitors such as dasatinib and imatinib might increase the risk of opportunistic infections, especially Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections. However, the effect of sorafenib on EBV and CMV infections remains unclear. The aim of this study was to investigate the effect of sorafenib maintenance post-transplantation on the incidence and mortality…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Effect of #sorafenib maintenance on #EpsteinBarrVirus and #cytomegalovirus infections in patients with FLT3-ITD #AML undergoing allogeneic #hematopoietic #stemcell transplantation: a secondary analysis of a #randomizedclinicaltrial New at #BMCMedicine - https://t.co/vugT58J5Fi https://t.co/f3W9XuCXqH
-
-
Mashup Score: 5
The phase 3 RATIONALE 301 trial of tislelizumab in patients with unresectable hepatocellular carcinoma has met its primary end point of non-inferior overall survival.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Tislelizumab met its primary end point of non-inferior overall survival compared with #sorafenib in the first-line in adult patients with unresectable hepatocellular carcinoma. #HCC https://t.co/JGrNI74uVF https://t.co/uzupaKxEep
-
-
Mashup Score: 2
Cabozantinib plus atezolizumab might be a treatment option for select patients with advanced hepatocellular carcinoma, but additional studies are needed.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI – in our August issue: #Cabozantinib plus #atezolizumab versus #sorafenib for advanced #hepatocellularcarcinoma #HCC (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial https://t.co/RMZ5MJ1hAQ
-
-
Mashup Score: 0
Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline lenvatinib and sorafenib therapy in metastatic HCC.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline #lenvatinib and #sorafenib therapy in metastatic #HCC. @MSKCancerCenter @NorthwesternMed @UTSWNews @HopkinsMedicine https://t.co/Q3XBfhDHCA
-
During a live virtual event, @GABOUALFA, MD, discussed the results of the REFLECT trial of #lenvatinib vs #sorafenib and the LEAP-002 trial of lenvatinib/#pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma. #lcsm #HCC | @MSKCancerCenter https://t.co/6fLE0Xl33W